Back Hepatitis C

Hepatitis C

EASL 2016: Grazoprevir/ Elbasvir Superior to Sofosbuvir Plus Pegylated Interferon

New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection. Results from the C-EDGE Head-to-Head study were presented at the recent EASL International Liver Congress in Barcelona.

alt

DDW 2016: ABT-493 + ABT-530 Cures Most Hepatitis C Patients in SURVEYOR Studies

A coformulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients with all hepatitis C virus (HCV) genotypes in a set of studies reported this week at the 2016 Digestive Disease Week meeting in San Diego.

alt

EASL 2016: Cost of Eliminating Viral Hepatitis Must Consider Social as Well as Medical Factors

Securing commitments from national governments to treat viral hepatitis, scale up prevention activities, and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces -- and a sophisticated approach to proving the value of investing in elimination of viral hepatitis -- delegates heard at last month’s EASL International Liver Congress.

alt

DDW 2016: Sofosbuvir/ Velpatasvir Produces High Hepatitis C Cure Rates in ASTRAL Trials

A coformulation of Gilead Science's sofosbuvir and its investigational hepatitis C virus (HCV) NS5A inhibitor velpatasvir taken for 12 weeks produced sustained virological response in 95% to 99% of participants across HCV genotypes and led to improvements in patient-reported outcomes, according to a pair of studies presented at the 2016 Digestive Disease Week meeting this week in San Diego.

alt

Hepatitis C Kills More People than Any Other Infectious Disease, CDC Says

The number of deaths due to hepatitis C is at an all-time high in the U.S. and exceeds those attributable to 60 other infectious diseases including HIV and tuberculosis, according to new surveillance data released this week by the Centers for Disease Control and Prevention (CDC). However, a related Italian study found that hepatitis C patients who are successfully treated have a life expectancy similar to that of the general population.

alt

May is Hepatitis Awareness Month -- Hepatitis Testing Day on May 19

May has been designated as Hepatitis Awareness Month in the U.S., an opportunity to raise awareness about viral hepatitis and to encourage testing and treatment. May 19 is the fifth annual observance of Hepatitis Testing Day, reminding health care providers and the public that more than half of the estimated 4-5 millionpeople living with chronic hepatitis B or C in the U.S. do not know they are infected.

alt

EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs

An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona. Between 86% and 100% of patients achieved sustained virological response and the combination worked well in the context of pre-existing resistance mutations.

alt

EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update Coming

In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the Screening, Care and Treatment of Patients with Chronic Hepatitis C Infection. The guidelines promote the transition to newer, more effective direct-acting antiviral (DAA) medications that have the potential to cure most people living with hepatitis C. Also during the meeting the European Association for the Study of the Liver (EASL) announced it would update its hepatitis C treatment guidelines at a special conference in September.

alt

EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains

People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.

alt